FindTrial
Sign In

control group:GEMOX

6 trials

Sponsors

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Cancer Center affiliated to Fudan University, First Affiliated Hospital of University of Science and Technology of China, the first affiliated hospital of Sun Yat-sen University, Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine

Conditions

Aggressive B cell lymphomaBiliary tract cancerbiliary tract cancersbiliary tract carcinomaextrahepatic cholangiocarcinoma and gallbladder carcinomaintrahepatic cholangiocarcinoma

Early Phase 1

A multicenter, randomized controlled trial of SHR1701 combined with GEMOX in treatment of biliary malignant tumor
Active, not recruitingChiCTR2000037146
Renji Hospital, Shanghai Jiaotong University School of Medicinebiliary tract carcinoma
Start: 2021-01-01Updated: 2020-10-05

Phase 2

Efficacy and safety of the GEMOX regimen in combination with or without tripleizumab for conversion to initially unresectable biliary tract cancer
RecruitingChiCTR2000039129
Shanghai Cancer Center affiliated to Fudan UniversityBiliary tract cancer
Start: 2020-05-11Updated: 2021-01-18

Phase 3

Randomized controlled trial of GemOx+/-R regimen in first-line treatment of elderly aggressive B cell lymphoma
Active, not recruitingChiCTR-TRC-12002256
JiangSu Province HospitalAggressive B cell lymphoma
Start: 2012-01-01Updated: 2017-04-18
Surufatinib plus GEMOX versus GEMOX as 1(st)-line treatment for unresectable or metastatic biliary tract cancers: a ramdomised, multicenter trial
Active, not recruitingChiCTR2300071465
the first affiliated hospital of Sun Yat-sen Universitybiliary tract cancers
Start: 2023-06-01Updated: 2023-06-12

Unknown Phase

A multicentre, open-label, randomised, controlled study of molecularly precision target therapy based on tumor molecular profiling with gemcitabine and oxaliplatin in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma
RecruitingChiCTR-IOR-16008729
Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicineextrahepatic cholangiocarcinoma and gallbladder carcinoma
Start: 2016-07-01Updated: 2017-04-18
A prospective randomized controlled study of DEB-TACE plus GEMOX in patients with unresectable intrahepatic cholangiocarcinoma
Active, not recruitingChiCTR2200062209
First Affiliated Hospital of University of Science and Technology of Chinaintrahepatic cholangiocarcinoma
Start: 2022-07-29Updated: 2023-04-03